PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study
2015 ◽
Vol 16
(3)
◽
pp. 284-292
◽
Keyword(s):
Phase 2
◽